Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Postpartum HPV Vaccination: Acceptability, Uptake and Immunogenicity

Trial Profile

Postpartum HPV Vaccination: Acceptability, Uptake and Immunogenicity

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2019 Planned End Date changed from 31 Jul 2019 to 31 Dec 2019.
    • 22 Jan 2019 Planned primary completion date changed from 28 Feb 2019 to 30 Sep 2019.
    • 22 Jan 2019 Planned initiation date changed from 15 Nov 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top